Diagnostiek en behandeling van pijn bij kanker


Pijn bij patiënten met kanker is meestal chronisch van karakter. Tegen de achtergrond van deze chronische pijn kan een plotselinge toename van pijn optreden, de zogenoemde doorbraakpijn. Deze CME Oncologie gaat over Doorbraakpijn.

This is a preview of subscription content, access via your institution.

Figuur 1
Figuur 2
Figuur 3
Figuur 4
Figuur 5


  1. 1

    Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331-8.

    PubMed  Article  Google Scholar 

  2. 2

    Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence- based recommendations from the EAPC. Lancet Oncol. 2012;13:e58-68.

    CAS  PubMed  Article  Google Scholar 

  3. 3

    Wengström Y, Geerling J, Rustoen T. European Oncology Nursing Society breakthrough cancer pain guidelines. Eur J Oncol Nurs. 2013 Dec 23. [Epub ahead of print]

  4. 4

    Davies A, Zeppetella G, Andersen S, et al. Multicentre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;13:756-63.

    Article  Google Scholar 

  5. 5

    Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013;46:619-28.

    PubMed  Article  Google Scholar 

  6. 6

    Deandrea S, Corti O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2014;47:57-76.

    PubMed  Article  Google Scholar 

  7. 7

    Portenoy RK. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273-81.

    CAS  PubMed  Article  Google Scholar 

  8. 8

    Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-34.

    CAS  PubMed  Article  Google Scholar 

  9. 9

    Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87-92.

    CAS  PubMed  Article  Google Scholar 

  10. 10

    Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177-83.

    PubMed  Article  Google Scholar 

  11. 11

    Zeppetella G. Breakthrough pain in cancer patients. Clin Oncol (R Coll Radiol). 2011;23:393-8.

    CAS  Article  Google Scholar 

  12. 12

    Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3:38-44.

    PubMed  Article  Google Scholar 

  13. 13

    Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587-93.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  14. 14

    Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611-6.

    CAS  PubMed  Article  Google Scholar 

  15. 15

    Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release ((MSIR). Pain. 2001;91:1123-30.

    Article  Google Scholar 

  16. 16

    Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodicbreakthrough pain. Br J Cancer. 2007;96:1828-33.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  17. 17

    Portenoy RK, Taylor D, Messina J, et al. A randomized, placebocontrolled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-11.

    PubMed  Article  Google Scholar 

  18. 18

    Slatkin NL, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioidtolerant patients with cancer-related pain. J Support Oncol. 2007;5:327-34.

    CAS  PubMed  Google Scholar 

  19. 19

    Kosugi T, Hamada S, Takigawa C, et al. A randomized, double-blind, placebo- controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients. J Pain Symptom Manage. 2013 Oct 5. [Epub ahead of print]

  20. 20

    Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21:1308-14.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  21. 21

    Rauck RL, Tark M, Reues E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrated tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877-85.

    CAS  PubMed  Article  Google Scholar 

  22. 22

    Lennernäs B, Frank-Lissbrant I, Lennernas H, et al. Sublingual administration of fentanyl to cancer patients is an effctive treatment for breakthrough pain: results from a randomized phase II study. Palliat Med. 2010;24:286-93.

    PubMed  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to A. De Graeff.

Additional information

Auteur Dr. A. de Graeff, internist-oncoloog/hospicearts, umc utrecht/academisch hospice demeter, de bilt

Bron: Oncologie Actueel, jaargang 16, nr. 1, maart 2014

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

De Graeff, A. Diagnostiek en behandeling van pijn bij kanker. MEDNET 7, 36–39 (2014). https://doi.org/10.1007/s12462-014-0242-9

Download citation